Related Experiment Videos
Lowering cholesterol: effects on trauma death, cancer death and total mortality
1Department of Medicine, Auckland Hospital, New Zealand.
Insights
Cholesterol reduction significantly lowers coronary heart disease (CHD) events and deaths. While total mortality reduction is observed, small, non-significant increases in cancer and trauma deaths suggest random variation.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Public Health
Background:
- Coronary heart disease (CHD) poses a significant global health burden.
- Cholesterol reduction therapies are widely used to mitigate cardiovascular risk.
Purpose of the Study:
- To evaluate the impact of cholesterol reduction on coronary heart disease incidence and overall mortality.
- To investigate potential associations between cholesterol-lowering treatments and non-cardiovascular causes of death.
Main Methods:
- Meta-analysis of 26 randomized controlled trials involving 50,000 patients.
- Assessment of net cholesterol reduction of approximately 10% across trials.
- Analysis of CHD events, CHD deaths, total mortality, cancer deaths, and trauma deaths.
Main Results:
- Significant reduction in the incidence of coronary heart disease (CHD) and non-fatal myocardial infarction (MI).
- CHD deaths reduced by approximately 10%, contributing to an expected 6% reduction in total mortality.
- Small, statistically non-significant excesses in cancer and trauma deaths were observed, not consistently linked to specific agents or trials.
Conclusions:
- Cholesterol reduction effectively reduces CHD incidence and mortality.
- Observed increases in non-cardiovascular deaths are likely due to chance and do not negate the benefits of cholesterol-lowering therapy.
- Further research may explore long-term safety profiles, but current evidence supports the cardiovascular benefits.
Abstract:
Randomised trials of cholesterol reduction (26 trials, 50,000 patients, net cholesterol reduction approximately 10%) have demonstrated a clear reduction in the incidence of coronary heart disease (CHD) after just a few years of treatment. Overall, the reduction in CHD death was only half as large as the reduction in non-fatal myocardial infarction (MI), although both were statistically significant (2P < 0.005). In these trials, 60% of all deaths were from CHD, and since treatment reduced these by about 10%, the expected reduction in total deaths was about 6%. This expected reduction falls within the 95% confidence interval of the observed effect of cholesterol reduction on total mortality in these trials. There were small excesses of deaths from cancer and deaths from trauma among patients allocated active treatment. However, in no single trial, nor in the trials collectively, were these increases statistically significant. Furthermore, the increases did not appear to be specific to any one agent nor were the increases consistent between trials of the same agent. These observations are consistent with the hypothesis that the small excesses of cancer and trauma deaths observed in the cholesterol reduction trials occurred by chance.